Earlier in May 2026, Pfizer reported positive Phase 2 results for its investigational 25‑valent pneumococcal conjugate ...

Pfizer (PFE) on Wednesday announced that it has begun a Phase 3 trial for its 25-valent pneumococcal vaccine, PF-07872412 (25vPnC), for infants after the shot outperformed its pneumococcal 20-valent ...

The inequalities gap in uptake rates of pneumococcal vaccine for vulnerable groups is widening and simplifying the vaccine schedule has not reduced this, researchers from the University of Liverpool ...

Vaccine uptake data has been examined to assess the impact of moving from a '2+1' to a '1+1' Pneumococcal Conjugate Vaccine (PCV) dose schedule on vaccine coverage and health inequalities among ...

-- Company Doses First Participants in Phase 2 Portion of Ongoing VAX-31 Phase 1/2 Study in Adults Following Independent Review of Phase 1 Safety and Tolerability Data; Topline Safety, Tolerability ...

In adults living with HIV, the 21-valent pneumococcal conjugate vaccine (PCV) V116 was well tolerated and effective against all 21 target serotypes. The immune responses were comparable to those ...

See more on Vaxcyte's (PCVX) and VAX-31’s broad pneumococcal vaccine pipeline, strong cash runway, and key 2026–2027 trial ...

After pneumococcal disease and colonization have been controlled through vaccination campaigns, a reduced pneumococcal conjugate vaccine (PCV) schedule may be sufficient to sustain that control at ...

Pneumococcal conjugate vaccines (PCVs) reduce disease and colonization by the serotypes they cover. As of now, the Advisory Committee on Immunization Practices (ACIP) recommends that PCV15 and PCV20 ...

1 dose ≥8wks after last PCV dose 12 No additional vaccine 6 PCV15 or PCV20 1 dose ≥8wks after last pneumococcal vaccine 8 If PCV15 used, also give PPSV23 ≥8wks after the last PCV dose if not ...